NEW YORK (AP) — U.S. Attorneys in New Jersey on Friday filed a lawsuit seeking a shutdown of three Actavis Inc. plants until they are brought into compliance with testing, manufacturing laws and FDA regulations.
The complaint requests that the court prevent Actavis Inc., Actavis Totowa, and executives Sigurdur Olafsson and Douglas Boothe from being involved in the making of drugs until the company is brought into compliance with Food and Drug Administration requirements for testing, quality control and test response, and ceases selling unapproved and misbranded drugs.




